Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 4 1Phase 1 1

Status

Unknown 2Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5Gynecologic 3Breast 2Thoracic 1Head & Neck 1Gastrointestinal 1Dermatologic 1

Conditions

Prostatic Neoplasms 33Ovarian Neoplasms 9Breast Neoplasms 9Pancreatic Neoplasms 8Metastatic Castration-resistant Prostate Cancer 5Carcinoma, Renal Cell 5Urinary Bladder Neoplasms 4Neoplasm Metastasis 4Triple Negative Breast Neoplasms 3Sarcoma 3Lymphoma, Non-Hodgkin 3Endometrial Neoplasms 3Carcinoma, Transitional Cell 3Wilms Tumor 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Prostatic Neoplasms, Castration-Resistant 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Lung Neoplasms 2Histiocytosis, Langerhans-Cell 2Hereditary Sensory and Autonomic Neuropathies 2Hepatoblastoma 2Glioma 2Ependymoma 2Central Nervous System Neoplasms 2Castration-Resistant Prostate Carcinoma 2Xanthogranuloma, Juvenile 1

Interventions

Sunitinib 145Nivolumab 144pembrolizumab 132Sorafenib 84Bevacizumab 77Everolimus 74cabozantinib 71pazopanib 65Axitinib 65Ipilimumab 62aldesleukin 52Magnetic Resonance Spectroscopy 45Cyclophosphamide 40Interleukin-2 38lenvatinib 37Specimen Handling 36Radiosurgery 36Interferon-alpha 32atezolizumab 30temsirolimus 27belzutifan 24Gemcitabine 23fludarabine phosphate 22avelumab 22Radiotherapy 19Interferon alpha-2 19Biopsy 18fludarabine 17durvalumab 17Nephrectomy 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × olaparib × Genitourinary × Clear all
NCT03682289 2026-04-23

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

University of California, San Francisco

Phase 2 Active not recruiting
83 enrolled
GastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Pancreatic Neoplasms, Endometrial Neoplasms

NCT03786796 2026-03-30

ORCHID

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Recruiting
20 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Terminated
221 enrolled
BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT05949424 2023-11-29

OPTI-DOSE

University Medical Center Groningen

Phase 4 Unknown
30 enrolled
BreastGenitourinaryGynecologicHead & Neck

Breast Neoplasms, Carcinoma, Renal Cell, Ovarian Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms

NCT03741426 2023-06-07

WIRE

Cambridge University Hospitals NHS Foundation Trust

Phase 2 Unknown
60 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡